Edwards Lifesciences Corporation (EW) exhibits 78.0% gross margins and 12.5% return on invested capital within Health Care (Industrial Specialties), balanced against a 35.1x enterprise multiple and 7.2% implied options volatility.
Sustained 78.0% gross profitability converts into 20.8% operating margin and 12.5% ROIC, outpacing sector cost of capital.
ROIC: 12.5% // GM: 78.0%YoY revenue trajectory of +11.5% paired with 2.45% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +11.5% // FCF YLD: 2.45%Altman Z-Score of 12.36 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 12.36 // F-SCORE: 8/9Trading at 50.7x trailing P/E (47.2x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 50.7x // EV/EBITDA: 35.1xOptions market prices a ±7.2% implied move with a 0.79 put/call ratio around $93.00 max pain.
IMPL MOVE: ±7.2% // P/C: 0.79Elevated industry capital intensity and customer concentration in Industrial Specialties require continuous execution to defend 17.7% net margins.
NET MARGIN: 17.7% // D/E: 0.06x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for EW & activate live FRED threshold breach alerts.